Login
Sen. Ron Johnson (R-Wis.) has written to The Lancet and The New England Journal of Medicine seeking records on two retracted studies from mid-2020. Johnson particularly called out The Lancet study, which suggested hydroxychloroquine could boost the risk of death in COVID patients.
“Although this fraudulent study was ultimately retracted, it is concerning and shameful that, in the midst of a pandemic, ‘The Lancet’ published such a misleading paper on a potential early treatment for COVID-19,” said Johnson, the ranking member on the Permanent Subcommittee on Investigations, in a letter dated Dec. 14.
Johnson seeks all records of the journals’ communication on the two studies, including communication with the papers’ authors; U.S. government employees; individuals who encouraged the studies’ publication; and the supplier of the two studies’ datasets, Surgisphere, a healthcare analytics company.
Despite The Lancet paper’s retraction, its initial publication halted trials on hydroxychloroquine’s use and sullied its reputation more broadly. The Washington Post and other major media headlined the increased risk of death, and health authorities took action globally within days of the paper’s publication.
The World Health Organization and the UK’s drug regulator halted trials of the drug in COVID settings. France reversed an earlier decision to allow hydroxychloroquine’s use in COVID patients.
Readers of The Lancet quickly noted the study cited implausibly high numbers of COVID cases in 2020, and journalists failed to find any hospitals that had contributed data, despite the study’s claim that more than 96,000 hospital patients participated.
The Lancet retracted the study two weeks after publication.
Sen. Johnson also requested information from The New England Journal of Medicine (NEJM) on another study retracted in June 2020.
Johnson explained in his letter, the NEJM paper reportedly found that “taking certain blood pressure drugs, including angiotensin-converting enzyme (ACE) inhibitors, didn’t appear to increase the risk of death among COVID-19 patients, as some researchers had suggested.”
However, the study’s authors wrote to the NEJM a few weeks after the study was published, acknowledging they could not validate the primary data supporting the study and apologized “to the editors and to readers of the Journal for the difficulties that this has caused.”
Johnson has requested all records by Jan. 4, 2022.
